Researchers reported a mechanistic oncology-adjacent immune finding: blocking the sugar-linkage enzyme ST6GAL1 reverses a “sugar switch” on macrophages, restoring tumor-fighting behavior and slowing colorectal cancer cell growth in lab studies. The work positions glycosylation control on immune cells as a lever for reprogramming tumor-associated macrophages. In parallel, researchers identified immune pathways that can amplify disease progression across autoimmune settings, including a role for IFIT1 in lupus progression through immune-cell death and cytokine production. Together, the findings highlight a shift from purely receptor-blocking strategies toward tuning immune-cell functional states—via enzymes and downstream signaling nodes—potentially enabling more targeted combination approaches.